Total
0
Shares
Oneview Healthcare (ASX:ONE) - CEO, James Fitter (left) and President & Founder, Mark McCloskey (right)
CEO, James Fitter (left) and President & Founder, Mark McCloskey (right)
Source: Silicon Republic
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Oneview Healthcare (ONE) has launched the world’s first cloud-based care experience platform, CXP Cloud Enterprise
  • The platform offers cloud deployment with features for both patients and care providers, like meal ordering, video chat, patient education and translation services
  • The company says this comes at a critical time to meet the demand for digital health services being driven by the pandemic
  • Following the news, Oneview shares jumped 24.14 per cent to trade for 36 cents each

Oneview Healthcare (ONE) has launched the world’s first cloud-based care experience platform, CXP Cloud Enterprise.

The platform, deployed on Microsoft Azure, enables health systems to quickly adopt technology for engaging patients, reducing non-clinical demands on care teams and optimising clinical and operational effectiveness.

CXP Cloud Enterprise offers a secure, reliable cloud deployment with patient education, meal ordering, service requests, apps and digital services, visitation, entertainment, video chat and translation services — all aiming to drive better control and quality care for both patients and care providers.

The platform was developed in partnership with NYU Langone Health, an academic medical centre in New York, which rapidly rolled out the virtual engagement platform across its facilities during the COVID-19 pandemic to address the increased pressure on care teams and patient’s restricted access to family and friends.

NYU Langone and Oneview collaborated on the initial cloud-based version that enabled the implementation of key capabilities across 400 beds in just weeks. According to the company, today’s launch now offers full function and integration of care capabilities in a faster, easier, more affordable cloud model at the bedside.

“Being the first and only cloud-based care experience solution gives us a strong competitive advantage and means health systems can rapidly implement the capabilities that meet their needs today while providing the agility, scalability and investment protection to grow as their health system changes,” said Chief Executive Officer James Fitter.

“We are excited to know that CXP Cloud Enterprise will help transform the hospital experience for patients, families and care teams.”

Dr Simon Kos, Healthcare Industry Executive at Microsoft Australia ,described the new platform as a game changer for the medical industry.

“It means that health organisations can deploy more quickly, with greater predictability and less specialised resources, all on the trusted Azure cloud. This is a win for patients, clinicians and healthcare organisations that put patient experience and outcomes first,” said Kos.  

The company says this comes at a critical time to meet the rising demand for digital health services being driven by the pandemic.

Oneview also released its annual report today, detailing at $9.1 million loss in 2021. This represents an improvement on a loss of nearly $17 million in the previous year.

Revenue for the year remained stable however, at just over $7 million.

Following the news, Oneview shares jumped 24.14 per cent to trade for 36 cents each at 10:31 am AEDT.

ONE by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.